Assessment of the Value of the Free Kappa and Free Lambda Light Chain Assay in Clinical Evaluation of Response to Treatment
N/A
N/A
N/A
N/A
N/A
Open (Enrolling)
Both
Multiple Myeloma
Both
Multiple Myeloma
Trial Information
Assessment of the Value of the Free Kappa and Free Lambda Light Chain Assay in Clinical Evaluation of Response to Treatment
Inclusion Criteria:
- diagnosis of multiple myeloma
- abnormal serum free light chains
- medical needs of anti-myeloma therapy
- receiving standard anti-myeloma therapy
Exclusion Criteria:
- dialysis
- normal serum free light chains
- dementia
Type of Study:
Observational
Study Design:
Time Perspective: Prospective
Outcome Measure:
Time to 50% reduction in the concentration of the abnormal serum free light chain compared to 50% reduction in M-protein
Outcome Time Frame:
1, 2, 3, 4 and 5 days, 2, 3 and 6 weeks after therapy,
Safety Issue:
No
Principal Investigator
Charlotte T Hansen, Fellow
Investigator Role:
Principal Investigator
Investigator Affiliation:
Department of Haematology, research unit
Authority:
Denmark: The Regional Committee on Biomedical Research Ethics
Study ID:
HFE-05-02
NCT ID:
NCT01423344
Start Date:
February 2011
Completion Date:
February 2012
Related Keywords:
- Multiple Myeloma
- multiple myeloma
- Free light chains
- Multiple Myeloma
- Neoplasms, Plasma Cell
Name | Location |
|---|
